2010
Genetic Associations of Brain Structural Networks in Schizophrenia: A Preliminary Study
Jagannathan K, Calhoun VD, Gelernter J, Stevens MC, Liu J, Bolognani F, Windemuth A, Ruaño G, Assaf M, Pearlson GD. Genetic Associations of Brain Structural Networks in Schizophrenia: A Preliminary Study. Biological Psychiatry 2010, 68: 657-666. PMID: 20691427, PMCID: PMC2990476, DOI: 10.1016/j.biopsych.2010.06.002.Peer-Reviewed Original ResearchConceptsSpecific structural brain abnormalitiesMagnetic resonance imaging (MRI) scansSmall sample sizeHealthy control subjectsStructural brain abnormalitiesStructural magnetic resonance imaging (MRI) scansGray matter deficitsResonance imaging scansCortical gray matterNormal central nervous system developmentRisk genesCentral nervous system developmentBrain structural networksControl subjectsImaging scansBrain abnormalitiesNervous system developmentIllness markersSchizophrenia pathophysiologySchizophrenia risk genesGenetic componentTemporal lobeBrain areasEuropean-American subjectsSchizophrenia patients
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity